NASDAQ: CNXU
Conexeu Sciences Inc.CIK 0002066836 · SIC 3842 · Orthopedic & Prosthetic Supplies
Micro by assets
Assets $8M
as of Sep 13, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (PANW 10-K) is open in full — no account needed.
424B3
Filed Sep 10, 2026
Summary not yet generated.
8-K
Filed Sep 10, 2026
· Period ending Sep 4, 2026
Summary not yet generated.
Partner
Trade CNXU commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed Jul 7, 2026
· Period ending Jul 7, 2026
Summary not yet generated.
424B3
Filed Jun 16, 2026
Summary not yet generated.
10-Q
Filed Jun 15, 2026
· Period ending Apr 30, 2026
Summary not yet generated.
8-K
Filed Jun 9, 2026
· Period ending Jun 4, 2026
Summary not yet generated.
424B3
Filed May 15, 2026
Summary not yet generated.
424B4
Filed May 11, 2026
Summary not yet generated.
S-1/A
Filed Apr 17, 2026
Summary not yet generated.
S-1/A
Filed Apr 10, 2026
Summary not yet generated.
S-1/A
Filed Apr 6, 2026
Summary not yet generated.
S-1
Filed Nov 28, 2025
Summary not yet generated.
Latest financial statements
From 10-Q filed Jun 15, 2026 (period ending Apr 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Statements of Operations (Unaudited)
| Description | Three months ended April 30, 2026 | Three months ended April 30, 2025 | Six months ended April 30, 2026 | Six months ended April 30, 2025 |
|---|---|---|---|---|
| OPERATING EXPENSES | ||||
| Advertising and promotion | 9,256 | 19,323 | 20,710 | 27,215 |
| Depreciation and amortization | 11,422 | 3,401 | 17,860 | 3,964 |
| Bank charges | 3,644 | 926 | 5,676 | 1,658 |
| Business development | 85,712 | 56,337 | 182,757 | 94,220 |
| Consulting | 1,228,909 | 149,586 | 1,759,107 | 196,596 |
| Filing fees | 17,618 | 150 | 25,258 | 150 |
| Insurance | 4,148 | - | 8,400 | - |
| Investor relations | 1,085 | - | 2,125 | - |
| Management and directors' salaries and fees related parties | 609,613 | 83,116 | 1,335,705 | 292,802 |
| Office and general administrative | 16,867 | 5,720 | 23,843 | 6,349 |
| Professional fees | 325,489 | 95,957 | 592,719 | 101,347 |
| Research and development | 66,605 | 42,465 | 129,167 | 66,133 |
| Total operating expenses | 2,380,368 | 456,981 | 4,103,327 | 790,434 |
| LOSS FROM OPERATIONS | (2,380,368) | (456,981) | (4,103,327) | (790,434) |
| OTHER INCOME (EXPENSES) | ||||
| Gain on conversion of payables | - | - | - | 43,176 |
| Interest income | 84,295 | - | 95,586 | - |
| Interest expense | - | (1,383) | - | (4,993) |
| Foreign exchange gain (loss) | (8,210) | 314 | (15,365) | 4,137 |
| Total other income (expenses) | 76,085 | (1,069) | 80,221 | 42,320 |
| LOSS BEFORE TAXES | (2,304,283) | (458,050) | (4,023,106) | (748,114) |
| Income tax benefit (expense) | - | - | - | - |
| NET LOSS | (2,304,283) | (458,050) | (4,023,106) | (748,114) |
| Net loss per common share, basic and diluted | (0.11) | (0.05) | (0.20) | (0.08) |
| Weighted average of common shares outstanding, basic and diluted | 20,569,664 | 9,505,618 | 20,567,442 | 9,184,944 |
Condensed Balance Sheets
| Description | April 30, 2026 | October 31, 2025 |
|---|---|---|
| CURRENT ASSETS | ||
| Cash and cash equivalents | 6,848,064 | 4,808,965 |
| Restricted cash | 453,974 | 25,155 |
| Share subscription receivable | - | 2,000,000 |
| Tax receivable | - | 3,037 |
| Interest receivable | 2,171 | - |
| Convertible note receivable | - | 71,326 |
| Prepaid expenses | 609,476 | 549,930 |
| TOTAL CURRENT ASSETS | 7,913,685 | 7,458,413 |
| NON-CURRENT ASSETS | ||
| Deferred offering costs | - | 42,177 |
| Investment, at cost | 71,328 | - |
| Security deposit | 12,317 | - |
| Fixed assets, net of accumulated depreciation of $10,712 and $7,431, respectively | 38,400 | 11,237 |
| Patent, net of accumulated amortization of $22,754 and $9,819, respectively | 163,949 | 176,884 |
| TOTAL ASSETS | 8,199,679 | 7,688,711 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | 455,055 | 256,296 |
| Accounts payable and accrued liabilities related parties | 71,309 | - |
| Wages payable | - | 76,000 |
| Shares to be issued under the warrant inducement program | 427,967 | - |
| Warrants to be issued under the warrant inducement program | 543 | - |
| Liabilities to be settled with shares | 44,700 | - |
| Due to shareholders | 3,722 | 3,722 |
| TOTAL LIABILITIES | 1,003,296 | 336,018 |
| COMMITMENTS AND CONTINGENCIES (See Notes 8 and 9) | ||
| SHAREHOLDERS' EQUITY | ||
| Preferred Stock, par value $0.001, 50,000,000 shares authorized, 0 shares issued and outstanding as of April 30, 2026 and October 31, 2025, respectively | - | - |
| Common Stock, par value $0.001, 250,000,000 shares authorized, 20,916,173 and 18,906,066 shares issued and outstanding as of April 30, 2026 and October 31, 2025, respectively | 20,916 | 18,906 |
| Additional paid-in capital | 15,720,093 | 11,855,307 |
| Accumulated deficit | (8,544,626) | (4,521,520) |
| TOTAL SHAREHOLDERS' EQUITY | 7,196,383 | 7,352,693 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 8,199,679 | 7,688,711 |
Statements of Cash Flows (Unaudited)
| Description | Six months ended April 30, 2026 | Six months ended April 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | (4,023,106) | (748,114) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Amortization expense | 12,935 | 1,133 |
| Depreciation expense | 4,925 | 2,831 |
| Fixed asset, disposed | 2,741 | - |
| Gain on conversion of payables | - | (43,176) |
| Options issued for services | 449,755 | 64,311 |
| Shares issued for conversion of payables | - | 26,686 |
| Shares to be issued for services | 44,698 | - |
| Changes in operating assets and liabilities: | ||
| Accounts payable and accrued liabilities | 198,759 | 164,161 |
| Accounts payable and accrued liabilities related parties | 71,309 | (52,738) |
| Interest receivable | (2,171) | - |
| Taxes receivable | 3,037 | (11,962) |
| Wages payable | (76,000) | - |
| Prepaid expenses | (59,546) | (133,737) |
| Security deposit | (12,317) | - |
| Liability to be settle by shares | 44,700 | 66,000 |
| Net cash used in operating activites | (3,340,281) | (664,605) |
| Cash flow from investing activities | ||
| Purchase of fixed assets | (34,829) | (18,268) |
| Change in convertible note receivables | (2) | - |
| Net cash used in investing activities | (34,831) | (18,268) |
| Cash flow from financing activities | ||
| Receivable form issuance of private placement shares | 2,000,000 | - |
| Repayments on due to shareholders | - | (4,190) |
| Shares to be issued for warrant inducements | 427,928 | - |
| Proceeds for warrants issued under the warrant inducement program | 564 | - |
| Proceeds received for performance warrants exercised | 500 | - |
| Proceeds from private placement, net of issuance costs | 2,943,351 | 550,000 |
| Repayment of loan payable | - | (98,117) |
| Offering costs paid for future offering | 42,177 | - |
| Proceeds received for warrants to be issued for warrant inducements | 543 | - |
| Proceeds received for shares to be issued for warrant inducements | 427,967 | - |
| Net cash provided by financing activities | 5,843,030 | 447,693 |
| Increase in cash, cash equivalents and restricted cash | 2,467,918 | (235,180) |
| Cash, cash equivalents and restricted cash at beginning of period | 4,834,120 | 314,616 |
| Cash, cash equivalents and restricted cash at end of period | 7,302,038 | 79,436 |
| Supplemental cash flow information | ||
| Cash paid for interest | - | 18,916 |
| Cash paid for taxes | - | - |
| Non-cash investing and financing activities | ||
| Investment | 71,328 | - |
| Shares issued for conversion of payables | - | 122,898 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗